Dose Escalation and Expansion Study of SAR444200 in Adult Participants With Advanced Solid Tumors - Trial NCT05450562
Access comprehensive clinical trial information for NCT05450562 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Sanofi and is currently Recruiting. The study focuses on Neoplasm. Target enrollment is 106 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sanofi
Timeline & Enrollment
Phase 1/2
Sep 29, 2022
May 11, 2029
Primary Outcome
Part 1A and 1B: Number of participants with Dose Limiting Toxicities (DLTs),Part 1A and 1B: Number of participants with Adverse Events (AEs),Part 2A: Objective Response Rate (ORR)
Summary
This is a single group, treatment, Phase 1/Phase 2, open label, multiple cohort,
 first-in-human study to evaluate safety and efficacy of SAR444200 as a monotherapy or in
 combination with other anti-cancer agents for participants aged at least 18 years with
 previously treated metastatic malignancies.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05450562
Non-Device Trial